Search

Your search keyword '"Li, Ziling"' showing total 2 results
Start Over Author "Li, Ziling" Publisher american diabetes association
2 results on '"Li, Ziling"'

1. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial

Author

Qu, Ling, primary, Liang, Xiaochun, primary, Tian, Guoqing, primary, Zhang, Gaili, primary, Wu, Qunli, primary, Huang, Xiumei, primary, Cui, Yazhong, primary, Liu, Yuling, primary, Shen, Zhufang, primary, Xiao, Changqing, primary, Qin, Yingfen, primary, Miao, Heng, primary, Zhang, Yongyan, primary, Li, Ziling, primary, Ye, Shandong, primary, Zhang, Xuezhi, primary, Yang, Jing, primary, Cao, Guiwen, primary, Li, Yi, primary, Yang, Gangyi, primary, Hu, Ji, primary, Wang, Xiaoyue, primary, Li, Zhengfang, primary, Li, Yukun, primary, Zhang, Xiuzhen, primary, Zhang, Guangde, primary, Chen, Li, primary, Hua, Wenjin, primary, Yu, Ming, primary, Lu, Chunyan, primary, Zhang, Xiaomei, primary, and Jiang, Hong, primary

Published
2021
Full Text
View/download PDF

2. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial.

Author

Qu, Ling, Liang, Xiaochun, Tian, Guoqing, Zhang, Gaili, Wu, Qunli, Huang, Xiumei, Cui, Yazhong, Liu, Yuling, Shen, Zhufang, Xiao, Changqing, Qin, Yingfen, Miao, Heng, Zhang, Yongyan, Li, Ziling, Ye, Shandong, Zhang, Xuezhi, Yang, Jing, Cao, Guiwen, Li, Yi, and Yang, Gangyi

Subjects
TYPE 2 diabetes, GLYCOSYLATED hemoglobin, CLINICAL trials, ANALYSIS of covariance, TWIGS, MULBERRY, THERAPEUTIC use of alkaloids, DRUG tablets, RESEARCH, COMBINATION drug therapy, RESEARCH methodology, BLOOD sugar, HYPOGLYCEMIC agents, MEDICAL cooperation, EVALUATION research, PLANTS, TREATMENT effectiveness, COMPARATIVE studies, RANDOMIZED controlled trials, BLIND experiment
Abstract

Objective: This study aimed to evaluate the efficacy and safety of mulberry twig alkaloids (Sangzhi alkaloids [SZ-A]) in the treatment of type 2 diabetes (T2D).Research Design and Methods: This was a multicenter, randomized, double-blind, double-dummy, and parallel controlled noninferiority clinical trial that was conducted for 24 weeks. A total of 600 patients were randomly allocated to the SZ-A group (n= 360) or acarbose group (n= 240). The primary efficacy end point was the change of glycosylated hemoglobin (HbA1c) compared with baseline. In addition, adverse events (AEs), severe AEs (SAEs), treatment-related AEs (TAEs), and gastrointestinal disorders (GDs) were monitored.Results: After treatment for 24 weeks, the change in HbA1c was -0.93% (95% CI -1.03 to -0.83) (-10.2 mmol/mol [-11.3 to -9.1]) and -0.87% (-0.99 to -0.76) (-9.5 mmol/mol [-10.8 to -8.3]) in the SZ-A and acarbose groups, respectively, and the least squares mean difference was -0.05% (95% CI -0.18 to 0.07) (-0.5 mmol/mol [-2.0 to 0.8]) between the two groups, with no significant difference on the basis of covariance analysis (P > 0.05). The incidence of TAEs and GDs was significantly lower in the SZ-A group than the acarbose group (P < 0.01), but no differences for AEs or SAEs between the two groups were observed (P > 0.05).Conclusions: SZ-A exhibited equivalent hypoglycemic effects to acarbose in patients with T2D. Nevertheless, the incidence of TAEs and GDs was lower following SZ-A treatment than acarbose treatment, suggesting good safety. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results